RecruitingPhase 3NCT07390123

Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

A Randomized, Double-blind, and Placebo-controlled Parallel Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of HSK39297 Tablets in Treatment of Patients With Primary IgAN

Sponsor

Haisco Pharmaceutical Group Co., Ltd.

Enrollment

370 participants

Start Date

Apr 7, 2026

Study Type

INTERVENTIONAL

Conditions

IgA Nephropathy (IgAN)

Summary

Evaluate the efficacy and safety of HSK39297 tablets in patients with primary IgAN

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called HSK39297 and a drug called Placebo for people with iga nephropathy (igan). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHSK39297

HSK39297 200mg, once a day; treatment period; 48-weeks fixed dose.

DRUGPlacebo

Placebo, once a day; treatment period; 48-weeks fixed dose.

Locations(9)

Huangshan City People's Hospital

Huangshan City, Anhui, China

The Second Affiliated Hospital of Wannan Medical College

Wuhu, Anhui, China

Peking University First Hospital

Beijing, Beijing Municipality, China

Zhanjiang Central Hospital

Zhanjiang, Guangdong, China

Xiangya Hospital of Central South University

Changsha, Hunan, China

The Second Hospital of Jilin University

Changchun, Jilin, China

Linyi City People Hospital

Linyi, Shandong, China

Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, China

Xijing Hospital

Xi’an, Shanxi, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07390123

Related Trials

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease

NCT073051161 location

A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases

NCT073894991 location